Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy - 20/05/21
Abstract |
Background |
A 31-gene genetic expression profile (31-GEP; Class 1 = low risk, Class 2 = high risk) developed to predict outcome in cutaneous melanoma (CM) has been validated by retrospective, industry-sponsored, or small series.
Methods |
Tumor features, sentinel node biopsy (SNB) results, and outcomes were extracted from a prospective database of 383 C M patients who underwent SNB and had a 31-GEP run on their primary tumor. Groups were compared by uni- and multi-variable analysis. Relapse-free and distant metastasis-free survival (RFS, DMFS) were estimated by Kaplan-Meier method.
Results |
Breslow thickness, T stage, and SNB positivity were significantly higher in Class 2 patients. Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive. GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients.
Conclusions |
31-GEP adds prognostic information in CM patents undergoing SNB.
Le texte complet de cet article est disponible en PDF.Highlights |
• | A 31-gene genetic expression profile (31-GEP) was developed to predict outcome in cutaneous melanoma (CM) patients. |
• | Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive. |
• | Both AJCC stage and GEP class were independently predictive of both RFS and DMF. |
• | GEP Class independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients. |
• | 31-GEP adds prognostic information in the evaluation of primary CM and should be considered in patents referred for SNB. |
Keywords : Melanoma, Genetic expression profiling, Sentinel node biopsy, Outcomes
Plan
Vol 221 - N° 6
P. 1195-1199 - juin 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?